SLC7A11 and ovarian carcinoma: Most of ovarian cancer patients carry wild‐type BRCA with no significant clinical benefits from PARP inhibitors; however, recent studies have shown that this subset of patients is sensitive to targeted‐SLC7A11 ferroptosis inducers.15